Research ArticleArticle
A Clinical, Pathological, and Genetic Characterization of Methotrexate-associated Lymphoproliferative Disorders
Noriyuki Yamakawa, Masakazu Fujimoto, Daisuke Kawabata, Chikashi Terao, Momoko Nishikori, Ran Nakashima, Yoshitaka Imura, Naoichiro Yukawa, Hajime Yoshifuji, Koichiro Ohmura, Takao Fujii, Toshiyuki Kitano, Tadakazu Kondo, Kimiko Yurugi, Yasuo Miura, Taira Maekawa, Hiroh Saji, Akifumi Takaori-Kondo, Fumihiko Matsuda, Hironori Haga and Tsuneyo Mimori
The Journal of Rheumatology December 2013, jrheum.130270; DOI: https://doi.org/10.3899/jrheum.130270
Noriyuki Yamakawa
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Masakazu Fujimoto
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Daisuke Kawabata
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Chikashi Terao
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Momoko Nishikori
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Ran Nakashima
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Yoshitaka Imura
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Naoichiro Yukawa
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Hajime Yoshifuji
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Koichiro Ohmura
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Takao Fujii
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Toshiyuki Kitano
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Tadakazu Kondo
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Kimiko Yurugi
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Yasuo Miura
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Taira Maekawa
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Hiroh Saji
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Akifumi Takaori-Kondo
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Fumihiko Matsuda
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Hironori Haga
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Tsuneyo Mimori
From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan. N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine. Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com. Accepted for publication October 8, 2013.
Article Information
jrheum.130270
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online December 15, 2013.
Article Versions
- You are currently viewing a Latest version of this article (December 15, 2013 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2013 The Journal of Rheumatology
Author Information
- Noriyuki Yamakawa,
- Masakazu Fujimoto,
- Daisuke Kawabata,
- Chikashi Terao,
- Momoko Nishikori,
- Ran Nakashima,
- Yoshitaka Imura,
- Naoichiro Yukawa,
- Hajime Yoshifuji,
- Koichiro Ohmura,
- Takao Fujii,
- Toshiyuki Kitano,
- Tadakazu Kondo,
- Kimiko Yurugi,
- Yasuo Miura,
- Taira Maekawa,
- Hiroh Saji,
- Akifumi Takaori-Kondo,
- Fumihiko Matsuda,
- Hironori Haga and
- Tsuneyo Mimori
- From the Department of Rheumatology and Clinical Immunology, the Department of Diagnostic Pathology, the Center for Genomic Medicine, and the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; the Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; the HLA Foundation Laboratory, Kyoto, Japan.
N. Yamakawa, MD, Department of Rheumatology and Clinical Immunology; M. Fujimoto, MD, the Department of Diagnostic Pathology; D. Kawabata, MD, PhD, Department of Rheumatology and Clinical Immunology; C. Terao, MD, PhD, Department of Rheumatology and Clinical Immunology, and the Center for Genomic Medicine; M. Nishikori, MD, PhD, Department of Hematology and Oncology; R. Nakashima, MD, PhD; Y. Imura, MD, PhD; N. Yukawa, MD, PhD; H. Yoshifuji, MD, PhD; K. Ohmura, MD, PhD; T. Fujii, MD, PhD, Department of Rheumatology and Clinical Immunology; T. Kitano, MD; T. Kondo, MD, PhD, Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; K. Yurugi; Y. Miura, MD, PhD; T. Maekawa, MD, PhD, Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital; H. Saji, BSc, HLA Foundation Laboratory; A. Takaori-Kondo, MD, PhD, Department of Hematology and Oncology; F. Matsuda, MD, PhD, Center for Genomic Medicine; H. Haga, MD, PhD, Department of Diagnostic Pathology; T. Mimori, MD, PhD, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine.
Address correspondence to Dr. D. Kawabata, Kyoto University, Department of Rheumatology and Clinical Immunology, Shogoin-Kawahara-cho, 54 Sakyo-ku, Kyoto 606-8507, Japan. E-mail: yakugo@gmail.com.
Accepted for publication October 8, 2013.
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
A Clinical, Pathological, and Genetic Characterization of Methotrexate-associated Lymphoproliferative Disorders
Noriyuki Yamakawa, Masakazu Fujimoto, Daisuke Kawabata, Chikashi Terao, Momoko Nishikori, Ran Nakashima, Yoshitaka Imura, Naoichiro Yukawa, Hajime Yoshifuji, Koichiro Ohmura, Takao Fujii, Toshiyuki Kitano, Tadakazu Kondo, Kimiko Yurugi, Yasuo Miura, Taira Maekawa, Hiroh Saji, Akifumi Takaori-Kondo, Fumihiko Matsuda, Hironori Haga, Tsuneyo Mimori
The Journal of Rheumatology Dec 2013, jrheum.130270; DOI: 10.3899/jrheum.130270
A Clinical, Pathological, and Genetic Characterization of Methotrexate-associated Lymphoproliferative Disorders
Noriyuki Yamakawa, Masakazu Fujimoto, Daisuke Kawabata, Chikashi Terao, Momoko Nishikori, Ran Nakashima, Yoshitaka Imura, Naoichiro Yukawa, Hajime Yoshifuji, Koichiro Ohmura, Takao Fujii, Toshiyuki Kitano, Tadakazu Kondo, Kimiko Yurugi, Yasuo Miura, Taira Maekawa, Hiroh Saji, Akifumi Takaori-Kondo, Fumihiko Matsuda, Hironori Haga, Tsuneyo Mimori
The Journal of Rheumatology Dec 2013, jrheum.130270; DOI: 10.3899/jrheum.130270